Benefits
Less UV-induced skin redness in one trial
In one randomized, placebo-controlled trial in 90 women with skin phototypes I to III and mild to moderate signs of skin ageing, taking the rosemary and grapefruit polyphenol combination by mouth reduced UV-induced skin redness compared with placebo, measured as the a* redness value after UVB and UVA exposure. Both the 100 mg and 250 mg doses performed the same. This is a single study funded and designed by the manufacturer, so treat it as promising rather than settled, and keep using sunscreen.
Lower oxidative damage marker (DNA damage was not measured)
The trial on this page did not measure DNA damage, and neither 8-OHdG nor cyclobutane pyrimidine dimers appear in it. What it did measure was malondialdehyde, a marker of oxidative damage to fats, which was lower in people taking the supplement. That is a laboratory marker. No study of this ingredient has looked at skin cancer, and nothing here should be read as reducing cancer risk.
Skin redness and inflammation reduction
The trial measured skin redness after controlled UVB and UVA exposure and found less redness in the supplement groups than in placebo. COX-2 and prostaglandin E2 were not measured in that trial, so the inflammation part of this explanation is laboratory theory rather than something shown in the people who took it. Duration of redness was not a reported outcome either.
Wrinkles and skin elasticity in one trial
In the same trial of 90 women, the supplement groups showed improved skin wrinkledness and improved skin elasticity compared with placebo. Collagen, matrix metalloproteases and protein crosslinking were not measured in anyone, so those are proposed explanations from laboratory work rather than trial results. Pigmentation was not reported either.
Complement to topical sunscreen
Nutroxsun® is not a replacement for topical SPF — the one trial that exists never compared it with a sunscreen or combined it with one, and it did not test whether it covers UV that gets past thin or missed sunscreen application. Sunscreen, shade and covering up remain the foundation of sun protection, and less redness in a study is not a reason to use less of them.
Mechanism of action
Antioxidant interception of UV-generated ROS
UV radiation generates reactive oxygen species (singlet oxygen, hydroxyl radicals, superoxide) in skin tissue that damage DNA, proteins, and lipid membranes even before causing visible redness. The proposed explanation is that these polyphenols reach skin tissue and mop up some of those reactive molecules. This comes from laboratory work. The human trial measured a marker of fat oxidation, malondialdehyde, and did not measure DNA damage at all.
COX-2 and inflammatory eicosanoid suppression
Rosmarinic acid and naringenin inhibit UV-induced COX-2 upregulation in keratinocytes, reducing prostaglandin E2 and other pro-inflammatory eicosanoids that drive erythema (redness), pain, and the inflammatory cascade that promotes photocarcinogenesis. This is a cell laboratory finding. The human trial measured redness after UV exposure but never measured COX-2 or prostaglandin E2, and it did not report a minimal erythemal dose result, so the link between the two is assumed rather than shown.
Nrf2 activation and endogenous antioxidant enzyme induction
In laboratory studies, carnosic acid (rosemary) and naringenin (grapefruit) switch on Nrf2, a control switch that raises the body's own antioxidant enzymes such as glutathione peroxidase, superoxide dismutase and catalase. None of these enzymes were measured in the human trial of this ingredient, so this stays a proposed mechanism rather than a demonstrated one.
Clinical trials
Randomized, placebo-controlled trial of the rosemary plus grapefruit polyphenol combination sold as Nutroxsun®, taken by mouth at 100 mg or 250 mg per day, in 90 women with skin phototypes I to III and mild to moderate signs of chrono- or photoageing. Outcomes included UV-induced skin redness, malondialdehyde, skin wrinkledness and skin elasticity. (Nobile et al. 2016, Food and Nutrition Research, PMID 27374032)
90 female participants with mild to moderate signs of skin ageing. Two active doses, 100 mg and 250 mg per day, compared with placebo.
Significant results: less UVB- and UVA-induced skin redness, lower malondialdehyde (a marker of oxidative damage to fats), improved skin wrinkledness and improved skin elasticity. No difference was found between the 100 mg and 250 mg doses, so paying for the higher dose bought nothing the study could detect. Limitations that matter: this is the only trial of the product, it was funded by Monteloeder and Nutrafur, Monteloeder designed the protocol and supplied the test product, one author worked for Monteloeder, and both companies were allowed to review the manuscript and suggest changes. It is not a sunscreen substitute.
The same 2016 paper also included a separate crossover pilot in only 5 people. A group that small cannot show whether something works; it is a setup exercise for the main study. There is no separate 12-week assessment behind this page.
5 participants in the crossover pilot. This is not the 90-person trial, and its results should never be quoted as if they came from it. There is no 20-person 2025 acute crossover in the reference cited on this page.
Nothing from a 5-person pilot should be treated as proof of an effect. Claims about a 2025 acute trial in 20 people, about increases in the minimal erythemal dose, and about collagen or MMP protection are not supported by the single reference cited on this page. The findings on reactive oxygen species, interleukin release and MMP-1/3 come from cell experiments in the laboratory, not from people. The results that are real, in 90 women, are on the trial card above.